NYAG Takes Action Against Public Company for Approving Insider 10b5-1 Plan

Key Takeaways

• NYAG sued CEO and firm over 10b5‑1 plan approval
• Action based on Martin Act, no scienter required
• SEC and DOJ declined charges, highlighting jurisdictional differences
• Companies must tighten executive trading plan vetting procedures
• NY jurisdiction asserted via NYSE listing and NY‑based adviser

Summary

The New York Attorney General filed civil insider‑trading actions under the Martin Act against a Delaware‑incorporated public company and its CEO for approving a Rule 10b5‑1 trading plan while the executive possessed material non‑public information. The NYAG claimed jurisdiction because the company’s shares trade on the NYSE, the trades used a New York‑based adviser, and New York investors were involved. Federal regulators – the SEC and DOJ – declined to bring charges, citing the higher scienter standard required under federal law. The alert warns issuers to strengthen their 10b5‑1 approval processes to avoid similar state‑level liability.

Pulse Analysis

State‑level enforcement of insider‑trading rules has taken a dramatic turn with the New York Attorney General invoking the Martin Act against a public company and its chief executive. Unlike the federal securities framework, which demands proof of scienter – a deliberate intent to defraud – the Martin Act imposes liability without that burden. This lower threshold allowed the NYAG to pursue claims despite the SEC and DOJ opting not to file charges, underscoring the strategic advantage regulators can gain by leveraging state statutes when federal avenues stall.

For corporate boards and compliance officers, the ruling signals an urgent need to overhaul Rule 10b5‑1 plan approvals. Robust procedures now include mandatory executive certifications confirming the absence of material non‑public information at plan adoption, comprehensive due‑diligence inquiries into recent operational developments, and layered sign‑offs involving general counsel and the chief financial officer during periods of material change. Documentation of each review step becomes critical, as it provides a defensible audit trail should regulators question the timing or rationale behind a trading plan.

The broader market impact may be a tightening of insider‑trading policies across U.S. issuers, particularly those listed on the NYSE or with significant New York investor bases. Companies are likely to consult external counsel more frequently to assess MNPI risks and to design safeguards that align with both federal and state expectations. As state attorneys general continue to assert jurisdiction based on market presence rather than corporate domicile, proactive compliance will be a decisive factor in mitigating legal exposure and preserving shareholder confidence.